コンテンツへスキップ
Merck
  • Suppression of adipogenesis by valproic acid through repression of USF1-activated fatty acid synthesis in adipocytes.

Suppression of adipogenesis by valproic acid through repression of USF1-activated fatty acid synthesis in adipocytes.

The Biochemical journal (2014-02-12)
Miki Yuyama, Ko Fujimori
要旨

VPA (valproic acid), a short-chain fatty acid that is a HDAC (histone deacetylase) inhibitor, is known to suppress adipogenesis. In the present study, we identified the molecular mechanism of VPA-mediated suppression of adipogenesis in adipocytes. VPA suppressed the accumulation of intracellular triacylglycerol. The expression levels of PPARγ (peroxisome-proliferator-activated receptor γ) and C/EBPα (CCAAT/enhancer-binding protein α), which are key regulators of adipogenesis, as well as the expression of SCD (stearoyl-CoA desaturase), were decreased by the treatment with VPA. Moreover, glycerol release was decreased in the VPA-treated cells, even though the transcription levels of ATGL (adipose triacylglycerol lipase), HSL (hormone-sensitive lipase) and MGL (monoacylglycerol lipase), all of which are involved in lipolysis, were elevated by the treatment with VPA. It is noteworthy that the expression level of FAS (fatty acid synthase) was significantly suppressed when the cells were cultured in medium containing VPA. Furthermore, VPA-mediated suppression of the accumulation of the intracellular triacylglycerols was prevented by the treatment with palmitic acid, a major product of FAS. The results of promoter-luciferase and chromatin immunoprecipitation assays demonstrated that USF1(upstream stimulating factor 1) bound to the E-box of the promoter region of the FAS gene. In addition, the expression of USF1 was decreased by the treatment with VPA. siRNA-mediated knockdown of the expression of the USF1 gene repressed adipogenesis along with the decreased expression of the FAS gene. The overexpression of USF1 enhanced both adipogenesis and the expression of FAS in VPA-treated cells. These results indicate that VPA suppressed adipogenesis through the down-regulation of USF1-activated fatty acid synthesis in adipocytes.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
パルミチン酸, ≥99%
Sigma-Aldrich
パルミチン酸, BioXtra, ≥99%
Sigma-Aldrich
パルミチン酸, ≥98%, FCC, FG
USP
パルミチン酸, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
パルミチン酸, ≥98% palmitic acid basis (GC)
USP
バルプロ酸, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
2-プロピルペンタン酸
Supelco
バルプロ酸 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
パルミチン酸, natural, 98%, FG
Supelco
バルプロ酸, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
パルミチン酸, analytical standard
Supelco
パルミチン酸, Pharmaceutical Secondary Standard; Certified Reference Material
バルプロ酸, European Pharmacopoeia (EP) Reference Standard
パルミチン酸, European Pharmacopoeia (EP) Reference Standard
Supelco
パルミチン酸, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
Anti-USF1 (AB2) antibody produced in rabbit, IgG fraction of antiserum